UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q


                Quarterly Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


                For the quarterly period ended February 26, 2000
                                               -----------------

                         Commission file number 1-11479
                                                -------

                                  E-Z-EM, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                  Delaware                          11-1999504
       -------------------------------          -------------------
       (State or other jurisdiction of           (I.R.S. Employer
        incorporation or organization)          Identification No.)


     717 Main Street, Westbury, New York               11590
   ----------------------------------------          ----------
   (Address of principal executive offices)          (Zip Code)


                                 (516) 333-8230
               --------------------------------------------------
               Registrant's telephone number, including area code


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                               Yes _X_     No ___

On April 7, 2000, there were 4,016,121 shares of the registrant's Class A Common
Stock outstanding and 5,912,548 shares of the registrant's  Class B Common Stock
outstanding.

                                  Page 1 of 29
                            Exhibit Index on Page 20


<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                                      INDEX
                                      -----


Part I:  Financial Information                                            Page
------   ---------------------                                            ----


     Item 1. Financial Statements


       Consolidated Balance Sheets - February 26, 2000 and
          May 29, 1999                                                    3 - 4


       Consolidated Statements of Earnings - thirteen and
          thirty-nine weeks ended February 26, 2000 and
          February 27, 1999                                                   5


       Consolidated Statement of Stockholders' Equity and
          Comprehensive Income - thirty-nine weeks ended
          February 26, 2000                                                   6


       Consolidated Statements of Cash Flows - thirty-nine weeks
          ended February 26, 2000 and February 27, 1999                   7 - 8


       Notes to Consolidated Financial Statements                        9 - 12


     Item 2. Management's Discussion and Analysis of Financial
                    Condition and Results of Operations                 13 - 18


     Item 3. Quantitative and Qualitative Disclosures About
                    Market Risk                                         18 - 19


Part II:  Other Information
-------   -----------------


     Item 6. Exhibits and Reports on Form 8-K                                20



                                       -2-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)


                                                         February 26,   May 29,
              ASSETS                                         2000         1999
                                                           -------      -------
                                                         (unaudited)   (audited)

CURRENT ASSETS
    Cash and cash equivalents                              $ 4,087      $ 8,073
    Debt and equity securities                               8,920        5,216
    Accounts receivable, principally
       trade, net                                           18,855       21,904
    Inventories                                             28,516       26,974
    Other current assets                                     5,181        4,151
                                                           -------      -------

          Total current assets                              65,559       66,318

PROPERTY, PLANT AND EQUIPMENT - AT COST,
    less accumulated depreciation and
    amortization                                            21,325       21,325

COST IN EXCESS OF FAIR VALUE OF NET ASSETS
    ACQUIRED, less accumulated amortization                    419          424

INTANGIBLE ASSETS, less accumulated
    amortization                                             2,193        2,328

DEBT AND EQUITY SECURITIES                                   6,637        3,015

OTHER ASSETS                                                 3,089        2,649
                                                           -------      -------

                                                           $99,222      $96,059
                                                           =======      =======



The accompanying notes are an integral part of these statements.

                                       -3-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                 (in thousands, except share and per share data)


                                                         February 26,   May 29,
    LIABILITIES AND STOCKHOLDERS' EQUITY                     2000        1999
                                                           --------    --------
                                                         (unaudited)   (audited)

CURRENT LIABILITIES
    Notes payable                                                      $  1,829
    Current maturities of long-term debt                   $    210         197
    Accounts payable                                          5,500       7,320
    Accrued liabilities                                       7,679       7,736
    Accrued income taxes                                        404         806
                                                           --------    --------

          Total current liabilities                          13,793      17,888

LONG-TERM DEBT, less current maturities                       1,449         477

OTHER NONCURRENT LIABILITIES                                  3,184       2,403
                                                           --------    --------

          Total liabilities                                  18,426      20,768
                                                           --------    --------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
    Preferred stock, par value $.10 per
       share - authorized, 1,000,000 shares;
       issued, none
    Common stock
      Class A (voting), par value $.10 per
        share - authorized, 6,000,000 shares;
        issued and outstanding 4,016,483 shares
        at February 26, 2000 and 4,035,346 shares
        at May 29, 1999 (excluding 36,773 shares
        held in treasury at February 26, 2000)                  402         403
      Class B (nonvoting), par value $.10 per
        share - authorized, 10,000,000 shares;
        issued and outstanding 5,888,895 shares
        at February 26, 2000 and 6,058,277 shares
        at May 29, 1999 (excluding 308,847 and
        12,100 shares held in treasury at February
        26, 2000 and May 29, 1999, respectively)                589         606
    Additional paid-in capital                               20,415      21,917
    Retained earnings                                        58,018      53,887
    Accumulated other comprehensive income (loss)             1,372      (1,522)
                                                           --------    --------

          Total stockholders' equity                         80,796      75,291
                                                           --------    --------

                                                           $ 99,222    $ 96,059
                                                           ========    ========


The accompanying notes are an integral part of these statements.

                                       -4-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                       CONSOLIDATED STATEMENTS OF EARNINGS
                                   (unaudited)
                      (in thousands, except per share data)

<TABLE>
<CAPTION>
                                            Thirteen weeks ended                  Thirty-nine weeks ended
                                       -------------------------------       -------------------------------
                                       February 26,       February 27,       February 26,       February 27,
                                           2000               1999               2000               1999
                                         --------           --------           --------           --------
<S>                                      <C>                <C>                <C>                <C>
Net sales                                $ 25,752           $ 26,618           $ 80,922           $ 78,791

Cost of goods sold                         14,647             15,426             44,500             45,392
                                         --------           --------           --------           --------

      Gross profit                         11,105             11,192             36,422             33,399
                                         --------           --------           --------           --------

Operating expenses
  Selling and administrative                8,971              8,214             26,640             24,291
  Research and development                  1,190              1,335              3,562              3,566
                                         --------           --------           --------           --------

    Total operating expenses               10,161              9,549             30,202             27,857
                                         --------           --------           --------           --------

      Operating profit                        944              1,643              6,220              5,542

Other income (expense)
  Interest income                             243                128                534                385
  Interest expense                            (61)               (66)              (180)              (189)
  Equity in losses of affiliate                                  (62)                                 (200)
  Other, net                                  (26)                26                 36                408
                                         --------           --------           --------           --------

      Earnings before income
        taxes                               1,100              1,669              6,610              5,946

Income tax provision                          584                710              2,479              1,989
                                         --------           --------           --------           --------

      NET EARNINGS                       $    516           $    959           $  4,131           $  3,957
                                         ========           ========           ========           ========

Earnings per common share
  Basic                                  $    .05           $    .10           $    .41           $    .39
                                         ========           ========           ========           ========

  Diluted                                $    .05           $    .09           $    .40           $    .38
                                         ========           ========           ========           ========

Weighted average common shares
  Basic                                     9,988             10,094             10,045             10,085
                                         ========           ========           ========           ========

  Diluted                                  10,410             10,321             10,285             10,338
                                         ========           ========           ========           ========
</TABLE>


The accompanying notes are an integral part of these statements.

                                       -5-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

     CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

                    Thirty-nine weeks ended February 26, 2000
                                   (unaudited)
                        (in thousands, except share data)

<TABLE>
<CAPTION>

                                        Class A                 Class B                             Accumulated
                                      common stock           common stock     Additional               other                 Compre-
                                  --------------------   -------------------    paid-in  Retained  comprehensive             hensive
                                   Shares       Amount    Shares      Amount    capital  earnings  income (loss)   Total     income
                                  ---------    -------   ---------   -------  ---------- --------  -------------  -------    ------
<S>                               <C>           <C>      <C>           <C>      <C>       <C>         <C>         <C>        <C>
Balance at May 29, 1999           4,035,346     $403     6,058,277     $606     $21,917   $53,887     $(1,522)    $75,291

Exercise of stock options            17,910        2       112,090       11         689                               702
Income tax benefits on
  stock options exercised                                                            79                                79
Compensation related to
  stock option plans                                                                  4                                 4
Purchase of treasury stock          (36,773)      (3)     (296,747)     (30)     (2,348)                           (2,381)
Issuance of stock                                           15,275        2          74                                76
Net earnings                                                                                4,131                   4,131    $4,131
Unrealized holding gain on debt
  and equity securities                                                                                  2,979      2,979     2,979
Foreign currency translation
  adjustments                                                                                              (85)       (85)      (85)
                                  ---------    -----     ---------    -----     -------   -------      -------    -------    ------

Comprehensive income                                                                                                         $7,025
                                                                                                                             ======

Balance at February 26, 2000      4,016,483     $402     5,888,895     $589     $20,415   $58,018       $1,372    $80,796
                                  =========    =====     =========    =====     =======   =======      =======    =======
</TABLE>


The accompanying notes are an integral part of this statement.

                                       -6-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)
                                 (in thousands)


                                                        Thirty-nine weeks ended
                                                      --------------------------
                                                      February 26,  February 27,
                                                          2000          1999
                                                        --------      --------
Cash flows from operating activities:
  Net earnings                                          $  4,131      $  3,957
  Adjustments to reconcile net earnings
    to net cash provided by operating
    activities
      Depreciation and amortization                        2,169         2,175
      Provision for doubtful accounts                         91           182
      Equity in losses of affiliate                                        200
      Deferred income tax provision                           37            25
      Other non-cash items                                    74            33
      Changes in operating assets and
        liabilities
          Accounts receivable                              2,958           115
          Inventories                                     (1,542)       (1,094)
          Other current assets                            (1,037)         (942)
          Other assets                                      (440)          (92)
          Accounts payable                                (1,820)          917
          Accrued liabilities                                (57)          487
          Accrued income taxes                              (432)           94
          Other noncurrent liabilities                       114           111
                                                        --------      --------

            Net cash provided by operating
              activities                                   4,246         6,168
                                                        --------      --------

Cash flows from investing activities:
  Additions to property, plant and
    equipment, net                                        (2,021)       (1,628)
  Available-for-sale securities
    Purchases                                            (22,339)      (18,643)
    Proceeds from sale                                    18,635        16,995
  Increase in certificates of deposit                                     (802)
                                                        --------      --------

      Net cash used in investing activities               (5,725)       (4,078)
                                                        --------      --------

Cash flows from financing activities:
  Repayments of debt                                      (1,044)       (1,252)
  Proceeds from issuance of debt                              26
  Proceeds from exercise of stock options,
    including related income tax benefits                    781           278
  Purchase of treasury stock                              (2,381)
  Proceeds from issuance of stock in connection
    with the stock purchase plan                               6             7
                                                        --------      --------

      Net cash used in financing activities               (2,612)         (967)
                                                        --------      --------

                                       -7-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
                                   (unaudited)
                                 (in thousands)


                                                        Thirty-nine weeks ended
                                                      --------------------------
                                                      February 26,  February 27,
                                                          2000          1999
                                                        --------      --------


Effect of exchange rate changes on
  cash and cash equivalents                             $    105      $   (624)
                                                        --------      --------

      (DECREASE) INCREASE IN CASH
        AND CASH EQUIVALENTS                              (3,986)          499

Cash and cash equivalents
  Beginning of period                                      8,073         4,654
                                                        --------     ---------

  End of period                                         $  4,087     $   5,153
                                                        ========     =========

Supplemental disclosures of cash flow information:
    Cash paid during the period for:
      Interest                                          $     75     $     117
                                                        ========     =========

      Income taxes (net of refunds of $6 and $4 in
        2000 and 1999, respectively)                    $  3,044     $   1,827
                                                        ========     =========




The accompanying notes are an integral part of these statements.

                                       -8-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                     February 26, 2000 and February 27, 1999
                                   (unaudited)


NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

     The  consolidated  balance sheet as of February 26, 2000, the  consolidated
     statement of stockholders'  equity and comprehensive  income for the period
     ended  February 26, 2000, and the  consolidated  statements of earnings and
     cash flows for the periods  ended  February 26, 2000 and February 27, 1999,
     have been prepared by the Company without audit. The  consolidated  balance
     sheet as of May 29, 1999 was derived  from audited  consolidated  financial
     statements.  In the opinion of management,  all adjustments  (which include
     only  normally  recurring  adjustments)  necessary  to  present  fairly the
     financial  position,  changes in  stockholders'  equity  and  comprehensive
     income,  results of operations and cash flows at February 26, 2000 (and for
     all periods presented) have been made.

     Certain  information  and  footnote   disclosures,   normally  included  in
     financial   statements  prepared  in  accordance  with  generally  accepted
     accounting principles, have been condensed or omitted. It is suggested that
     these  consolidated  financial  statements be read in conjunction  with the
     financial  statements and notes thereto  included in the fiscal 1999 Annual
     Report on Form 10-K filed by the Company on August 27, 1999. The results of
     operations  for the periods  ended  February 26, 2000 and February 27, 1999
     are not necessarily  indicative of the operating results for the respective
     full years.

     The consolidated  financial statements include the accounts of E-Z-EM, Inc.
     and  all  100%-owned   subsidiaries   (the   "Company").   All  significant
     intercompany balances and transactions have been eliminated.  The Company's
     approximate  23% interest in an affiliate in fiscal 1999 was  accounted for
     by the equity method. Pursuant to this method, such investment was recorded
     at cost and adjusted by the Company's share of  undistributed  earnings (or
     losses).  In the  fourth  quarter of the prior  fiscal  year,  the  Company
     recorded an impairment  charge, as it was determined that the fair value of
     such investment was zero, with no future cash flows  anticipated due to the
     affiliate's   inability  to  generate   income  from  operations  or  raise
     additional capital.


NOTE B - INVENTORIES

     Inventories consist of the following:

                                                   February 26,          May 29,
                                                      2000                1999
                                                   ------------          -------
                                                           (in thousands)

       Finished goods                                $13,854             $14,000
       Work in process                                 2,666               1,926
       Raw materials                                  11,996              11,048
                                                     -------             -------

                                                     $28,516             $26,974
                                                     =======             =======


                                       -9-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     February 26, 2000 and February 27, 1999
                                   (unaudited)


NOTE C - EARNINGS PER COMMON SHARE

     In accordance with Statement of Financial Accounting Standards ("SFAS") No.
     128,  "Earnings  Per Share," the  Company has  presented  basic and diluted
     earnings  per share.  Basic  earnings  per share are based on the  weighted
     average  number of  common  shares  outstanding  without  consideration  of
     potential  common  stock.  Diluted  earnings  per  share  are  based on the
     weighted average number of common and potential common shares  outstanding.
     The  calculation  takes into  account  the shares  that may be issued  upon
     exercise of stock  options,  reduced by the shares that may be  repurchased
     with the funds  received  from the  exercise,  based on the  average  price
     during the period.

     The following table sets forth the  reconciliation  of the weighted average
     number of common shares:

<TABLE>
<CAPTION>
                                                    Thirteen weeks ended                  Thirty-nine weeks ended
                                               -------------------------------       -------------------------------
                                               February 26,       February 27,       February 26,       February 27,
                                                   2000               1999               2000               1999
                                                  ------             ------             ------             ------
                                                                           (in thousands)

<S>                                                <C>               <C>                <C>                <C>
       Basic                                       9,988             10,094             10,045             10,085
       Effect of dilutive
         securities (stock
         options)                                    422                227                240                253
                                                  ------             ------             ------             ------

       Diluted                                    10,410             10,321             10,285             10,338
                                                  ======             ======             ======             ======
</TABLE>

NOTE D - COMMON STOCK

     Under the 1983 and 1984 Stock Option Plans, options for 172,359 shares were
     granted at $5.63 per share,  options for 130,000  shares were  exercised at
     prices  ranging  from $3.66 to $7.54 per share,  options for 13,947  shares
     were forfeited at prices ranging from $4.22 to $8.58 per share, and options
     for 5,970 shares expired at $10.73 per share during the  thirty-nine  weeks
     ended February 26, 2000.  Under the 1997  AngioDynamics  Stock Option Plan,
     options for 6.53 shares were granted at $40,000 per share, options for 1.14
     shares were  forfeited at $40,000 per share,  and no options were exercised
     or expired during the thirty-nine weeks ended February 26, 2000.

     Under the Employee  Stock  Purchase  Plan,  1,275 shares were  purchased at
     $4.46 per share during the thirty-nine weeks ended February 26, 2000.

     In January 1999, the Board of Directors  authorized the repurchase of up to
     500,000  shares  of the  Company's  Class B Common  Stock  at an  aggregate
     purchase price of up to $2,000,000. In October 1999, the Board modified the
     program to include the Company's  Class A Common Stock.  In February  2000,
     the Board further  modified the program to increase the aggregate  purchase
     price of Class A and Class B Common Stock by an additional  $2,000,000.  As
     of February 26, 2000, the Company had repurchased  36,773 shares of Class A
     Common Stock and 308,847  shares of Class B Common Stock for  approximately
     $2,450,000.


                                      -10-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     February 26, 2000 and February 27, 1999
                                   (unaudited)


NOTE E - COMPREHENSIVE INCOME

     During  fiscal  1999,  the  Company   adopted  SFAS  No.  130,   "Reporting
     Comprehensive Income." SFAS No. 130 establishes new rules for the reporting
     and  display of  comprehensive  income  and its  components;  however,  the
     adoption  of SFAS No. 130 had no impact on the  Company's  net  earnings or
     stockholders'  equity.  SFAS No. 130 requires  unrealized  holding gains or
     losses on debt and  equity  securities  available-for-sale  and  cumulative
     translation  adjustments,  which prior to adoption were reported separately
     in stockholders'  equity, to be included in accumulated other comprehensive
     income (loss).

     The components of comprehensive income, net of related tax, are as follows:

                                                   Thirty-nine weeks ended
                                                  ------------------------------
                                                  February 26,     February 27,
                                                     2000              1999
                                                    -------          -------
                                                         (in thousands)

      Net earnings                                  $ 4,131          $ 3,957
      Unrealized holding gain on debt
        and equity securities                         2,979              248
      Foreign currency translation
        adjustments                                     (85)          (1,031)
                                                    -------          -------

          Comprehensive income                      $ 7,025          $ 3,174
                                                    =======          =======

     The components of accumulated  other  comprehensive  income (loss),  net of
     related tax, are as follows:

                                                  February 26,       May 29,
                                                     2000              1999
                                                    -------          -------
                                                         (in thousands)

      Unrealized holding gain on debt
        and equity securities                       $ 4,173          $ 1,193
      Cumulative translation adjustments             (2,801)          (2,715)
                                                    -------          -------

          Accumulated other comprehensive income
            (loss)                                  $ 1,372          $(1,522)
                                                    =======          =======


NOTE F - OPERATING SEGMENTS

     In fiscal  1999,  the  Company  adopted  SFAS No. 131,  "Disclosures  about
     Segments of an Enterprise and Related Information". The statement redefines
     how operating  segments are determined  and requires  disclosure of certain
     financial and descriptive information about a company's operating segments.
     The Company has adopted the new requirements retroactively.

     The  Company is  engaged  in the  manufacture  and  distribution  of a wide
     variety of  products  which are  classified  into two  operating  segments:
     Diagnostic  products  and  AngioDynamics   products.   Diagnostic  products
     encompass both contrast systems,  consisting of barium sulfate formulations
     and related

                                      -11-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     February 26, 2000 and February 27, 1999
                                   (unaudited)


NOTE F - OPERATING SEGMENTS (continued)

     medical  devices  used in X-ray,  CT-scanning,  ultrasound  and MRI imaging
     examinations,  and non-contrast  systems,  including  diagnostic  radiology
     devices,  custom  contract  pharmaceuticals,   gastrointestinal   cleansing
     laxatives, X-ray protection equipment, and immunoassay tests. AngioDynamics
     products include angiography, therapeutic and coronary medical devices used
     in the interventional medical marketplace.

     The Company's chief operating decision maker utilizes operating segment net
     earnings  (loss)  information in assessing  performance  and making overall
     operating  decisions  and  resource  allocations.   Information  about  the
     Company's segments is as follows:

<TABLE>
<CAPTION>
                                               Thirteen weeks ended                   Thirty-nine weeks ended
                                       ---------------------------------         ---------------------------------
                                       February 26,         February 27,         February 26,         February 27,
                                           2000                 1999                 2000                 1999
                                         --------             --------             --------             --------
                                                                      (in thousands)
     <S>                                <C>                  <C>                  <C>                  <C>
     Net sales from external
     customers
       Diagnostic products
         Contrast systems               $ 14,044             $ 14,911             $ 47,249             $ 44,788
         Non-contrast systems              6,806                7,166               19,904               18,859
                                        --------             --------             --------             --------

         Total Diagnostic products        20,850               22,077               67,153               63,647
       AngioDynamics products              4,902                4,541               13,769               15,144
                                        --------             --------             --------             --------

     Total net sales from external
       customers                        $ 25,752             $ 26,618             $ 80,922             $ 78,791
                                        ========             ========             ========             ========

     Intersegment net sales
       Diagnostic products              $   --               $      9             $      2             $     35
       AngioDynamics products                494                  129                  819                  383
                                        --------             --------             --------             --------

     Total intersegment net sales       $    494             $    138             $    821             $    418
                                        ========             ========             ========             ========

     Net earnings (loss)
       Diagnostic products              $    805             $  1,413             $  5,442             $  4,325
       AngioDynamics products               (296)                (454)              (1,354)                (365)
       Eliminations                            7                 --                     43                   (3)
                                        --------             --------             --------             --------

     Total net earnings                 $    516             $    959             $  4,131             $  3,957
                                         ========             ========             ========             ========

<CAPTION>
                                                                                 February 26,         February 27,
                                                                                     2000                 1999
                                                                                   --------             --------
                                                                                          (in thousands)
<S>                                                                                <C>                 <C>
     Assets
       Diagnostic products                                                         $111,547            $107,027
       AngioDynamics products                                                        17,710              17,922
       Eliminations                                                                 (30,035)            (28,890)
                                                                                   --------            --------

     Total assets                                                                  $ 99,222            $ 96,059
                                                                                   ========            ========
</TABLE>


                                      -12-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
                OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Quarters ended February 26, 2000 and February 27, 1999
------------------------------------------------------

     The Company's  quarters  ended February 26, 2000 and February 27, 1999 both
represent thirteen weeks.

Results of Operations
---------------------

     Segment Overview
     ----------------

     The Company  operates in two  industry  segments:  Diagnostic  products and
AngioDynamics  products. The Diagnostic products operating segment includes both
contrast systems and non-contrast systems. The AngioDynamics  products operating
segment includes  angiography,  therapeutic and coronary medical devices used in
the interventional medical marketplace.

<TABLE>
<CAPTION>
                                          Diagnostic       AngioDynamics        Eliminations           Total
                                          ----------       -------------        ------------           -----
                                                                       (in thousands)

Quarter ended February 26, 2000
-------------------------------

<S>                                        <C>                <C>                 <C>                 <C>
 Unaffiliated customer sales               $20,850            $ 4,902                --               $25,752
 Intersegment sales                           --                  494             ($  494)               --
 Gross profit                                8,513              2,585                   7              11,105
 Operating profit (loss)                       959                (22)                  7                 944

Quarter ended February 27, 1999
-------------------------------

 Unaffiliated customer sales               $22,077            $ 4,541                --               $26,618
 Intersegment sales                              9                129             ($  138)               --
 Gross profit (loss)                         9,117              2,078                  (3)             11,192
 Operating profit (loss)                     2,059               (416)               --                 1,643
</TABLE>

     Diagnostic Products
     -------------------

     Diagnostic  segment  operating  results for the current quarter declined by
$1,100,000 due primarily to decreased  sales and increased  operating  expenses.
Net sales  decreased  6%, or  $1,227,000,  due to lower demand for sales of both
contrast systems and non-contrast  systems. The lower sales demand resulted,  in
part, from the stocking of higher inventory levels by the Company's distributors
in the second  quarter,  in  anticipation of potential Year 2000 ("Y2K") related
supply issues.  Price increases  accounted for  approximately 5% of net sales in
the current quarter. Gross profit expressed as a percentage of net sales was 41%
during both the current  quarter as well as the comparable  quarter of the prior
year, as the  favorable  affect of sales price  increases  offset the effects of
increased  provision for  inventory  reserves of $346,000.  Increased  operating
expenses of $496,000 can be attributed to increased  selling and  administrative
expenses,  resulting,  in part, from investment in new product introductions and
selling and marketing initiatives.

     AngioDynamics Products
     ----------------------

     AngioDynamics segment operating results for the current quarter improved by
$394,000 due primarily to increased  sales and improved gross profit.  Net sales
increased  8%, or $361,000,  due  primarily to the  introduction  of several new
products, namely Abscession(TM) fluid drainage catheters, VistaFlex(TM) platinum
biliary stents, and Workhorse(TM) PTA balloon  catheters,  in the second quarter
of the current fiscal year. Gross profit expressed as a percentage of net sales

                                      -13-

<PAGE>

improved  to 48% during the  current  quarter  versus 45% during the  comparable
quarter of the prior year due  primarily to decreased  provision  for  inventory
reserves of $243,000.

     Consolidated Results of Operations
     ----------------------------------

     For the quarter ended February 26, 2000, the Company  reported net earnings
of  $516,000,  or $.05 per common  share on both a basic and diluted  basis,  as
compared to net  earnings of  $959,000,  or $.10 and $.09 per common  share on a
basic and diluted basis,  respectively,  for the comparable period of last year.
Results for the current  quarter were adversely  affected by decreased sales and
increased  operating  expenses in the Diagnostic  segment,  partially  offset by
increased sales and improved gross profit in the AngioDynamics segment.

     Net  sales  for the  quarter  ended  February  26,  2000  decreased  3%, or
$866,000,  as compared to the quarter  ended  February 27, 1999 due to decreased
sales of contrast  systems of $867,000  and  non-contrast  systems of  $360,000,
partially offset by increased sales of AngioDynamics products of $361,000. Price
increases  accounted for  approximately  4% of net sales in the current quarter.
Net sales in  international  markets,  including  direct  exports from the U.S.,
decreased 8%, or $708,000,  in the current quarter versus the comparable  period
of last  year  due to  decreased  sales of  non-contrast  systems  of  $459,000,
including  $373,000 relating to custom  contracts,  contrast systems of $151,000
and AngioDynamics products of $98,000.

     Gross profit expressed as a percentage of net sales increased to 43% during
the current  quarter versus 42% during the comparable  quarter of the prior year
due to improved  gross profit in the  AngioDynamics  segment,  resulting  from a
decrease in provision for inventory reserves of $243,000.

     Selling and  administrative  ("S&A")  expenses were  $8,971,000  during the
quarter  ended  February  26, 2000 versus  $8,214,000  during the quarter  ended
February 27, 1999. This increase of $757,000,  or 9%, in the current quarter was
due primarily to increased Diagnostic S&A expenses, which can be attributed,  in
part,  to  investment  in new product  introductions  and selling and  marketing
initiatives.

     Research and development ("R&D") expenditures  decreased 11% in the current
quarter to $1,190,000,  or 5% of net sales, from $1,335,000, or 5% of net sales,
in the comparable  quarter of the prior year.  This decline was due primarily to
decreased contrast system spending of $65,000 and AngioDynamics project spending
of $45,000.  Of the R&D expenditures in the current quarter,  approximately  47%
relate to contrast systems, 35% to AngioDynamics  projects,  2% to immunological
projects,  4% to  other  projects  and  12% to  general  regulatory  costs.  R&D
expenditures are expected to continue at approximately current levels.

     Other  income,  net of other  expenses,  totaled  $156,000 of income in the
current quarter versus $26,000 of income in the comparable  period of last year.
This  improvement  was due primarily to increased  interest  income of $115,000,
resulting  from the investment of additional  funds provided by operations,  and
the  recording  of the  Company's  approximate  23%  share in the  losses of ITI
Medical  Technologies,  Inc. ("ITI") of $62,000 in the comparable period of last
year,  partially offset by increased foreign currency exchange losses of $58,000
in the current quarter.

     The Company's  effective tax rate of 53% during the quarter ended  February
26, 2000  differed  from the Federal  statutory tax rate of 34% due primarily to
the fact that the  Company  did not  provide  for the tax  benefit  on losses in
certain  foreign  jurisdictions,  since it is more  likely  than  not that  such
benefits will not be realized. Losses incurred in a foreign jurisdiction subject
to lower tax rates and non-deductible expenses also contributed to the unusually
high effective tax rate, but were partially  offset by earnings of the Company's
Puerto

                                      -14-

<PAGE>

Rican  subsidiary,  which are subject to favorable U.S. tax  treatment.  For the
quarter  ended  February  27,  1999,  the  Company's  effective  tax rate of 43%
differed  from the Federal  statutory  tax rate of 34% due primarily to the fact
that the  Company  did not  provide  for the tax  benefit on losses  incurred in
certain  jurisdictions,  since,  at that time,  it was more likely than not that
such benefits would not be realized,  partially offset by earnings of the Puerto
Rican subsidiary, which are subject to favorable U.S. tax treatment.

Thirty-nine weeks ended February 26, 2000 and February 27, 1999
---------------------------------------------------------------

Results of Operations
---------------------

     Segment Overview
     ----------------

<TABLE>
<CAPTION>
                                          Diagnostic       AngioDynamics        Eliminations           Total
                                          ----------       -------------        ------------           -----
                                                                     (in thousands)

<S>                                        <C>                <C>                 <C>                 <C>
Thirty-nine weeks ended February 26, 2000
-----------------------------------------

 Unaffiliated customer sales               $67,153            $13,769                --               $80,922
 Intersegment sales                              2                819               ($821)               --
 Gross profit                               29,681              6,700                  41              36,422
 Operating profit (loss)                     7,015               (838)                 43               6,220

Thirty-nine weeks ended February 27, 1999
-----------------------------------------

 Unaffiliated customer sales               $63,647            $15,144                --               $78,791
 Intersegment sales                             35                383               ($418)               --
 Gross profit (loss)                        26,127              7,293                 (21)             33,399
 Operating profit (loss)                     5,697               (152)                 (3)              5,542
</TABLE>

     Diagnostic Products
     -------------------

     Diagnostic  segment  operating  results for the current period  improved by
$1,318,000 due to increased sales and improved gross profit, partially offset by
increased  operating  expenses.  Net sales  increased 6%, or $3,506,000,  due to
price increases and increased demand for sales of both contrast systems and non-
contrast systems. Price increases accounted for approximately 4% of net sales in
the current period. Gross profit expressed as a percentage of net sales improved
to 44% during the current period, versus 41% during the comparable period of the
prior year due  primarily  to sales price  increases  and  increased  production
throughput.  Increased  operating  expenses of  $2,236,000  can be attributed to
increased  S&A  expenses,  resulting,  in part,  from  investment in new product
introductions and selling and marketing initiatives.

     AngioDynamics Products
     ----------------------

     AngioDynamics  segment operating results for the current period declined by
$686,000 due primarily to decreased sales and gross profit.  Net sales decreased
9%, or  $1,375,000,  due primarily to lower than expected  sales of  Pulse*Spray
products,  resulting from the suspension of the sale of the clot-dissolving drug
abbokinase  by Abbott  Laboratories  in the  domestic  marketplace,  and reduced
international  sales,  resulting,  in large part, from the continued  decline in
sales of coronary stents. Abbokinase is the primary drug used in connection with
the Company's  Pulse*Spray  products.  Gross profit expressed as a percentage of
net sales  decreased  to 46% during  the  current  period  versus 47% during the
comparable  period of the  prior  year due  primarily  to  decreased  production
throughput  at both the  Queensbury,  New York and Irish  facilities,  partially
offset by decreased provision for inventory reserves of $329,000.

     Consolidated Results of Operations
     ----------------------------------

     For the thirty-nine weeks ended February 26, 2000, the Company reported net

                                      -15-

<PAGE>

earnings of $4,131,000, or $.41 and $.40 per common share on a basic and diluted
basis, respectively, as compared to net earnings of $3,957,000, or $.39 and $.38
per common share on a basic and diluted basis, respectively,  for the comparable
period of last year.  Results for the current period were favorably  affected by
increased sales and improved gross profit in the Diagnostic  segment,  partially
offset by decreased sales and gross profit in the AngioDynamics segment, as well
as increased operating expenses in the Diagnostic segment.

     Net sales for the  thirty-nine  weeks ended February 26, 2000 increased 3%,
or $2,131,000,  as compared to the thirty-nine weeks ended February 27, 1999 due
to increased sales of contrast systems of $2,461,000 and non-contrast systems of
$1,045,000,  partially  offset by decreased sales of  AngioDynamics  products of
$1,375,000.  Price increases  accounted for approximately 3% of net sales in the
current period.  Net sales in  international  markets,  including direct exports
from the U.S.,  increased  3%, or  $914,000,  in the current  period  versus the
comparable  period of last year due to  increased  sales of contrast  systems of
$1,421,000 and non-contrast systems of $492,000,  including $367,000 relating to
custom contracts,  partially offset by decreased sales of AngioDynamics products
of $999,000.

     Gross profit expressed as a percentage of net sales increased to 45% during
the current period versus 42% during the  comparable  period of last year due to
improved gross profit in the  Diagnostic  segment,  partially  offset by reduced
gross profit in the AngioDynamics  segment. The improved Diagnostic gross profit
expressed as a percentage of net sales is due primarily to sales price increases
and increased production  throughput.  The decreased  AngioDynamics gross profit
expressed as a percentage of net sales is due primarily to decreased  production
throughput at both the  Queensbury  and Irish  facilities,  partially  offset by
decreased provision for inventory reserves of $329,000.

     S&A expenses were $26,640,000  during the thirty-nine  weeks ended February
26, 2000 versus  $24,291,000  during the  thirty-nine  weeks ended  February 27,
1999.  This  increase  of  $2,349,000,  or 10%,  in the  current  period was due
primarily to increased  Diagnostic  S&A expenses,  which can be  attributed,  in
part,  to  investment  in new product  introductions  and selling and  marketing
initiatives.

     R&D expenditures in the current period were $3,562,000, or 4% of net sales,
versus $3,566,000,  or 5% of net sales, during the comparable prior year period.
There were no materially  significant  factors  affecting the  comparison of R&D
expenditures in the current period versus the comparable  prior year period.  Of
the R&D expenditures in the current period, approximately 47% relate to contrast
systems,  34% to AngioDynamics  projects,  3% to immunological  projects,  4% to
other projects and 12% to general regulatory costs.

     Other  income,  net of other  expenses,  totaled  $390,000 of income in the
current period versus $404,000 of income in the comparable  period of last year.
The  decline in foreign  currency  exchange  gains and losses of  $365,000,  was
offset by the recording of the Company's  approximate 23% share in the losses of
ITI of $200,000 in the comparable  period of last year,  and increased  interest
income of $149,000,  resulting from the investment of additional  funds provided
by operations.

     The Company's  effective tax rate of 38% during the thirty-nine weeks ended
February  26,  2000  differed  from the  Federal  statutory  tax rate of 34% due
primarily  to the fact that the  Company  did not provide for the tax benefit on
losses in certain foreign  jurisdictions,  since it is more likely than not that
such  benefits  will not be  realized.  Earnings of the  Company's  Puerto Rican
subsidiary,  which are subject to favorable U.S. tax  treatment,  were offset by
losses  incurred in a foreign  jurisdiction  subject to lower tax rates and non-
deductible  expenses.  For the  thirty-nine  weeks ended  February 27, 1999, the
Company's effective tax rate of 33% differed from the Federal statutory tax rate
of 34% due primarily to the utilization of previously unrecorded tax credit

                                      -16-

<PAGE>

carryforwards and earnings of the Puerto Rican subsidiary,  which are subject to
favorable U.S. tax treatment,  partially offset by the fact that the Company did
not  provide for the tax  benefit on losses  incurred in certain  jurisdictions,
since, at that time, it was more likely than not that such benefits would not be
realized, and non-deductible expenses.

Liquidity and Capital Resources
-------------------------------

     During the  thirty-nine  weeks ended  February  26,  2000,  the purchase of
treasury  stock,  capital  expenditures  and debt repayments were funded by cash
provided  by  operations.   The  Company's  policy  has  been  to  fund  capital
requirements  without  incurring  significant  debt. At February 26, 2000,  debt
(notes  payable,  current  maturities of long-term debt and long-term  debt) was
$1,659,000 as compared to $2,503,000 at May 29, 1999.  The Company has available
$5,452,000  under two bank lines of credit of which no amounts were  outstanding
at February 26, 2000.

     At February 26, 2000,  approximately 61% of the Company's assets consist of
inventories,  accounts  receivable,  short-term debt and equity securities,  and
cash and cash  equivalents.  The  current  ratio is 4.75 to 1, with net  working
capital of $51,766,000 at February 26, 2000, as compared to the current ratio of
3.71 to 1, with net working capital of $48,430,000 at May 29, 1999.

     In January 1999, the Board of Directors  authorized the repurchase of up to
500,000  shares of the Company's  Class B Common Stock at an aggregate  purchase
price of up to  $2,000,000.  In October 1999,  the Board modified the program to
include the Company's  Class A Common Stock. In February 2000, the Board further
modified the program to increase  the  aggregate  purchase  price of Class A and
Class B Common Stock by an additional  $2,000,000.  As of February 26, 2000, the
Company had repurchased 36,773 shares of Class A Common Stock and 308,847 shares
of Class B Common Stock for approximately $2,450,000.

     Year 2000 Compliance
     --------------------

     Management  developed  and  completed  its  plan to  modify  the  Company's
information  technology to recognize  the Year 2000.  The Year 2000 issue is the
result of computer  programs  being written using two digits rather than four to
define the applicable year. The plan had three distinct areas of focus;  namely,
traditional   information  systems,   technology  used  in  support  areas,  and
preparedness of suppliers and customers.

     The  first  area of focus  was an  assessment  of  traditional  information
technology, namely internal software business applications, hardware and desktop
support. All of the Company's software systems, applications and desktop support
have been assessed, modified and tested to be Year 2000 compliant.

     The second area of focus was an assessment  of  technology  used in support
areas,  which includes the  electronics in  manufacturing  equipment,  telephone
systems,  security  systems  and  payroll  time  clocks.  At the  present  time,
substantially  all such  equipment  has either  been  tested to assure Year 2000
compliance or has been certified by vendors to be Year 2000 compliant.

     The third area of focus was communications  with suppliers and customers to
understand  their level of readiness  and assure a constant flow of materials to
support  business plans. The Company sought  compliance  statements from each of
its significant suppliers. Communication has shown a high level of awareness and
planning by these parties,  most of which have provided  positive  assurances to
maintain a constant flow of materials. At the present time, no material problems
or concerns are indicated by these responses.  However,  if a significant vendor
or  customer is  non-compliant,  the  Company  can give no  assurance  that such
occurrence will not have an adverse affect on the Company's results. The Company
believes its action plans will minimize these risks and prevent any major

                                      -17-

<PAGE>

interruptions in the flow of materials and products.

     Formal  contingency plans were not formulated since the Company  identified
no  specific  areas  where there was a  substantial  risk of year 2000  problems
occurring.

     The plan was administered by internal staff and management.  Costs incurred
in the Company's readiness effort, which approximated $130,000, were expensed as
incurred,  except  for  those  costs  capitalized  as fixed  assets.  Management
believes  that the  Company  has met its  compliance  goals and,  to date,  this
project has not had a material  impact on the  Company's  operations,  though no
future assurance can be given in this regard.

     Forward-Looking Statements
     --------------------------

     This Form 10-Q  contains  certain  forward-looking  statements  within  the
meaning  of  Section  27A of  the  Securities  Act  of  1933,  as  amended  (the
"Securities  Act"),  and Section 21E of the Securities  Exchange Act of 1934, as
amended  (the  "Exchange  Act"),  which are  intended  to be covered by the safe
harbors  created  thereby.  Investors  are  cautioned  that all  forward-looking
statements  involve risks and uncertainty,  including  without  limitation,  the
ability of the  Company  to  develop  its  products,  as well as general  market
conditions,  competition  and pricing.  Although the Company  believes  that the
assumptions  underlying  the  forward-looking  statements  contained  herein are
reasonable, any of the assumptions could be inaccurate, and therefore, there can
be no assurance that the  forward-looking  statements included in this Form 10-Q
will prove to be accurate. In light of the significant uncertainties inherent in
the   forward-looking   statements   included  herein,  the  inclusion  of  such
information  should not be  regarded as a  representation  by the Company or any
other person that the objectives and plans of the Company will be achieved.


Item 3.  Quantitative and Qualitative Disclosures About Market Risk
         ----------------------------------------------------------

     The  Company  is exposed to market  risk from  changes in foreign  currency
exchange rates and, to a much lesser extent,  interest rates on investments  and
financing,  which could impact results of operations and financial position. The
Company does not  currently  engage in hedging or other  market risk  management
tools.  There  have  been no  material  changes  with  respect  to  market  risk
previously disclosed in the fiscal 1999 Annual Report on Form 10-K.

     Foreign Currency Exchange Rate Risk
     -----------------------------------

     The Company's  international  subsidiaries  are  denominated  in currencies
other  than the U.S.  dollar.  However,  since the  functional  currency  of the
Company's  international  subsidiaries is the local currency,  foreign  currency
translation  adjustments  are  accumulated as a component of  accumulated  other
comprehensive  income (loss) in  stockholders'  equity.  Assuming a hypothetical
change in the foreign  currency  versus the U.S. dollar exchange rates of 10% at
February  26, 2000,  the  Company's  assets and  liabilities  would  increase or
decrease by $2,347,000 and $606,000,  respectively,  and the Company's net sales
and  net  earnings  would  increase  or  decrease  by  $2,303,000  and  $47,000,
respectively, on an annual basis.

     The Company also maintains  intercompany balances and loans receivable with
subsidiaries  with  different  local  currencies.  These  amounts are at risk of
foreign  exchange  losses if exchange rates  fluctuate.  Assuming a hypothetical
change in the foreign  currency  versus the U.S. dollar exchange rates of 10% at
February  26, 2000,  results of  operations  would be  favorably or  unfavorably
impacted by approximately $1,006,000 on an annual basis.


                                      -18-

<PAGE>

     Interest Rate Risk
     ------------------

     The Company is exposed to interest  rate change market risk with respect to
its  investments in tax-free  municipal  bonds in the amount of $8,885,000.  The
bonds bear interest at a floating rate  established  weekly.  During the thirty-
nine weeks ended February 26, 2000, the interest rate on the bonds  approximated
3.7%.  Each 100 basis point (1%)  fluctuation in interest rates will increase or
decrease  interest  income on the bonds by  approximately  $89,000  on an annual
basis.

     As  the  Company's  principal  amount  of  fixed  interest  rate  financing
approximates  $1,659,000 at February 26, 2000, a change in interest  rates would
not materially impact results of operations or financial  position.  At February
26, 2000, the Company did not maintain any variable interest rate financing.




                                      -19-

<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           Part II: Other Information


Item 6.  Exhibits and Reports on Form 8-K
         --------------------------------

(a)  Exhibits
     --------

     No.         Description                                            Page
     ---         -----------                                            ----

      3        1983 Stock Option Plan                                    21

     27        Financial data schedule                                   29

(b)  Reports on Form 8-K
     -------------------

     No reports on Form 8-K were filed  during the quarter  ended  February  26,
     2000.


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                            E-Z-EM, Inc.
                                            ----------------------------------
                                            (Registrant)




Date April 11, 2000                         /s/ Anthony A. Lombardo
     --------------------                   ----------------------------------
                                            Anthony A. Lombardo, President and
                                            Chief Executive Officer




Date April 11, 2000                         /s/ Dennis J. Curtin
     --------------------                   ----------------------------------
                                            Dennis J. Curtin, Senior Vice
                                            President - Chief Financial Officer



                                      -20-